. 2009 Jun 22;53(9):3642–3649. doi: 10.1128/AAC.00206-09

TABLE 4.

Activities of vancomycin, teicoplanin, daptomycin, tigecycline, ceftobiprole, and linezolid against hVISA/VISA and VSSA strains

Group	Antimicrobial agent^b	Susceptibility categorization^c						Cumulative % of isolates inhibited at MIC (mg/liter) of:
Group	Antimicrobial agent^b	% R	% I	% S	MIC₅₀ (mg/liter)	MIC₉₀ (mg/liter)	MIC range (mg/liter)	0.125	0.25	0.5	1.0	2.0	4.0	16
hVISA/VISA^a (n = 27)	VAN	0	3.7	96.3	1	2	0.5-4	0.0	0.0	3.70	85.2	96.3	100	100
hVISA/VISA^a (n = 27)	TEC	0	0	100	2	8	0.5-8	0.0	0.0	3.70	25.9	66.7	85.2	100
	DAP	0	0	100	0.5	1	0. 25-1	0.0	14.8	88.9	100	100	100	100
	TGC	0	0	100	0.25	0.25	0.032-0.5	44.4	92.6	100	100	100	100	100
	BPR	0	0	100	2	2	1-4	0.0	0.0	11.1	33.3	96.3	100	100
	LZD	0	0	100	1	2	0.5-2.0	0.0	0.0	33.3	85.2	100	100	100
VSSA (n = 173)	VAN	0	0	100	1	1	0.5-2	0.0	0.0	35.8	99.4	100	100	100
	TEC	0	0	100	2	4	0.125-4	0.58	2.89	12.1	49.1	79.8	100	100
	DAP	0	0	100	0.5	0.5	0.125-1	0.58	10.7	95.1	100	100	100	100
	TGC	0	0	100	0.125	0.25	0.032-0.5	54.3	90.2	100	100	100	100	100
	BPR	0	0	100	2	2	0.25-2	0.0	2.31	4.62	27.2	100	100	100
	LZD	0	0	100	1	2	0.125-2	0.58	1.16	31.2	82.7	100	100	100

The MICs for the VISA strain were as follows: vancomycin, 4 mg/liter; teicoplanin, 8 mg/liter; daptomycin, 0.5 mg/liter; tigecycline, 0.25 mg/liter; ceftobiprole, 0.5 mg/liter; and linezolid, 1 mg/liter.

VAN, vancomycin; TEC, teicoplanin; DAP, daptomycin; TGC, tigecycline; BPR, ceftobiprole; LZD, linezolid.

R, resistant; I, intermediate; S, susceptible.